New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops
A study of over 280,000 adults found that the shingles vaccine reduced dementia risk by 20%, with a stronger effect in women.
Shingles is awful, but there may be another reason to get vaccinated. It may fight dementia
Shingrix is a onetime vaccination, given in two doses a few months apart. The CDC recommends it starting at age 50 for most ...
GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs
Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
Shingles vaccine may also cut risk of dementia, study shows
A vaccine to fight dementia? It turns out there may already be one – shots that prevent painful shingles also appear to ...
Shingles Vaccine Can Decrease Risk of Dementia, Study Finds
Several previous studies have suggested that shingles vaccinations might reduce dementia risk, but most could not exclude the ...
Nasdaq14d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
GSK’s Vaccine sales declined 3% globally and 27% in the United States in 2024 due to lower sales of the shingles vaccine, Shingrix and RSV vaccine, Arexvy. U.S. sales of Shingrix declined 13% ...
Medscape15d
Recombinant Zoster Vaccine Proved Effective in Patients With Rheumatoid Arthritis
This study was supported by funds from GSK, which makes Shingrix. Four authors were employed at GSK during the study and held financial equities in the company. Other authors disclosed receiving ...